# RARG

Source: https://onco.cc/targets/rarg/  
OnCo record `rarg` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RARG (Retinoic acid receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.

## Summary

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5.

Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.94, animal model 0.75, genetic association 0.18, clinical 0.97).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: retinoic acid receptor gamma; Retinoic acid receptor gamma; NR1B3; RARgamma; RAR-gamma
- Tags: cancer-genes-wave
- Symbol: RARG
- Class: transcription
- Biology: Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function. Location: Nucleus; Cytoplasm (UniProt). Locus 12q13.13 (HGNC).
- Where found: Leukaemia: Open Targets association 0.61 with leukaemia (MONDO_0005059); Myeloproliferative neoplasms: Open Targets association 0.61 with myeloproliferative neoplasm (MONDO_0020076); Acute myeloid leukaemia: Open Targets association 0.61 with acute myeloid leukaemia (MONDO_0018874); Acute promyelocytic leukaemia: Open Targets association 0.60 with acute promyelocytic leukaemia (MONDO_0012883)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9866: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9866
- UniProt P13631: https://www.uniprot.org/uniprotkb/P13631/entry
- NCBI Gene 5916: https://www.ncbi.nlm.nih.gov/gene/5916
- Ensembl ENSG00000172819: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172819

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Acute promyelocytic leukaemia](https://onco.cc/cancers/apl/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)

---
JSON: https://onco.cc/api/v1/entities/rarg.json